WuXi Biologics (Cayman) Inc. provided group earnings guidance for the six months ended June 30, 2019. For the six months ended June 30, 2019, it is expected that the profit attributable to equity shareholders of the Company for the six months ended June 30, 2019 will increase more than 78% compared with the profit attributable to equity shareholders of the Company for the corresponding period of last year. The increase is primarily due to: (i) leading technology platform, competitive timeline and strong execution track record contributing to more market share and new integrated projects being added to the company's pipeline; (ii) the Group's innovative proprietary technology platforms, including but not limited to the bispecific antibody technology platform WuXiBodyTM, have been more adopted in the industry; (iii) strong growth in revenue, as a result of the success of the Group's "Follow-the-Molecule" strategy; (iv) improvement of operational efficiency; and (v) other non-operating income recorded.